Wrapping up Q4 earnings, we look at the numbers and key takeaways for the beverages, alcohol, and tobacco stocks, including Vita Coco (NASDAQ: COCO) and its peers.

These companies' performance is influenced by brand strength, marketing strategies, and shifts in consumer preferences. Changing consumption patterns are particularly relevant and can be seen in the rise of cannabis, craft beer, and vaping or the steady decline of soda and cigarettes. Companies that spend on innovation to meet consumers where they are with regards to trends can reap huge demand benefits while those who ignore trends can see stagnant volumes. Finally, with the advent of the social media, the cost of starting a brand from scratch is much lower, meaning that new entrants can chip away at the market shares of established players.

The 13 beverages, alcohol, and tobacco stocks we track reported a satisfactory Q4. As a group, revenues beat analysts’ consensus estimates by 2.1% while next quarter’s revenue guidance was in line.

Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 5.5% since the latest earnings results.

Vita Coco (NASDAQ: COCO)

Founded in 2004 followed by a 2021 IPO, The Vita Coco Company (NASDAQ: COCO) offers coconut water products that are a natural way to quench thirst.

Vita Coco reported revenues of $127.8 million, flat year on year. This print exceeded analysts’ expectations by 6.2%. Overall, it was an exceptional quarter for the company with a solid beat of analysts’ EBITDA estimates and an impressive beat of analysts’ adjusted operating income estimates.

Vita Coco delivered the weakest full-year guidance update of the whole group. Unsurprisingly, the stock is down 6.2% since reporting and currently trades at $52.99.

We think Vita Coco is a good business, but is it a buy today? Read our full report here, it’s free.

Best Q4: Celsius (NASDAQ: CELH)

With its proprietary MetaPlus formula as the basis for key products, Celsius (NASDAQ: CELH) offers energy drinks that feature natural ingredients to help in fitness and weight management.

Celsius reported revenues of $721.6 million, up 117% year on year, outperforming analysts’ expectations by 13.5%. The business had an exceptional quarter with a solid beat of analysts’ EBITDA estimates and a solid beat of analysts’ revenue estimates.

Celsius achieved the biggest analyst estimates beat and fastest revenue growth among its peers. Although it had a fine quarter compared its peers, the market seems unhappy with the results as the stock is down 13% since reporting. It currently trades at $44.06.

Is now the time to buy Celsius? Access our full analysis of the earnings results here, it’s free.

Weakest Q4: Altria (NYSE: MO)

Best known for its Marlboro brand of cigarettes, Altria (NYSE: MO) offers tobacco and nicotine products.

Altria reported revenues of $5.08 billion, flat year on year, exceeding analysts’ expectations by 1.1%. Still, it was a slower quarter as it posted a miss of analysts’ EBITDA estimates and a miss of analysts’ adjusted operating income estimates.

Interestingly, the stock is up 6.9% since the results and currently trades at $67.49.

Read our full analysis of Altria’s results here.

Constellation Brands (NYSE: STZ)

With a presence in more than 100 countries, Constellation Brands (NYSE: STZ) is a globally renowned producer and marketer of beer, wine, and spirits.

Constellation Brands reported revenues of $2.22 billion, down 9.8% year on year. This number beat analysts’ expectations by 2.9%. Overall, it was a very strong quarter as it also produced a solid beat of analysts’ EBITDA estimates and an impressive beat of analysts’ organic revenue estimates.

The stock is up 4.8% since reporting and currently trades at $147.30.

Read our full, actionable report on Constellation Brands here, it’s free.

Keurig Dr Pepper (NASDAQ: KDP)

Born out of a 2018 merger between Keurig Green Mountain and Dr Pepper Snapple, Keurig Dr Pepper (NASDAQ: KDP) is a consumer staples powerhouse boasting a portfolio of beverages including sodas, coffees, and juices.

Keurig Dr Pepper reported revenues of $4.50 billion, up 10.5% year on year. This result topped analysts’ expectations by 3.1%. More broadly, it was a mixed quarter as it also logged an impressive beat of analysts’ revenue estimates but a miss of analysts’ gross margin estimates.

The stock is down 5.3% since reporting and currently trades at $28.19.

Read our full, actionable report on Keurig Dr Pepper here, it’s free.

Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.